Literature DB >> 2046538

Comparative evaluation of two membrane-based liposomal MRI contrast agents.

S Karlik1, E Florio, C W Grant.   

Abstract

Two phospholipids--one bearing a nitroxide free radical covalently attached to its polar headgroup, and the other bearing a similarly attached chelating agent with bound gadolinium--were compared in vivo as liposomal contrast agents for MR imaging. In each case the phospholipid contrast agent was incorporated into the membranes of sonicated unilamellar vesicles. The agent with bound gadolinium proved to be considerably more potent at highlighting regions of liposome biodistribution than did its spin-labelled analogue. Injected intramuscularly into rats, the spin-label liposomes produced local tissue contrast that persisted for 1 h; while under similar conditions, the liposomal gadolinium persisted for over 24 h. By comparison, water-soluble, nonliposomal DTPA-Gd3+ (dimeglumine), was rapidly cleared from the same intramuscular sites--appearing in kidney bladder within 15 min of injection. When delivered intravenously, maximum effect from both liposomal agents was observed in liver and spleen within 1-2 h, although the spin-label agent produced only marginal contrast. The concomitant use of fat suppression proved a valuable adjunct to liposomal contrast for imaging organs of the reticuloendothelial system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046538     DOI: 10.1002/mrm.1910190106

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  2 in total

Review 1.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.

Authors:  G Gregoriadis; A T Florence
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.